Peculiar age distribution of clinically significant recurring chromosome abnormalities was found as a result of investigation of526AML patients (249 children and 277 adults). Thus t(8;21) was more frequently detected in age from 2 to 10 years, t(15;17) was extremely rare in children under 5 years, rearrangements of 11q23 region were observed in more than half of patients under 24 months, inv(16) was most characteristic for patients in age 16-20 years; patients who were older than 51 years have showed a comparatively high incidence of normal karyotype (no chromosome abnormalities).

There were defined some chromosome characteristics of AML observed in children in age under 24 months. No patients with normal karyotype and chromosome translocations t(8;21) and t(15;17) associated with good risk were detected, but 11q23 rearrangements and complex karyotype were found significantly more frequent than in older children and adults.

Cytogenetic features of AML in different age groups with their hematopoietic peculiarities can be useful for clarification of mechanisms of specific chromosome abnormalities origin.

Based on the treatment results of 819 patients we formulated new approaches for combined treatment of Hodgkin’s lymphoma stages I-IV. It was constructed a simplified prognostic model and developed new alternating chemotherapy regimens. We demonstrated the possibility of reducing the number of courses of chemotherapy to 4 in poor prognosis cases and the dispensability of achieving a complete effect after execution of medication period, emphasized the important role of a subradical programme, the expediency of zonal reduction offields, and the necessity of irradiating the whole volume of a lymphatic collector in the doses not greater than 30 Gy.

The above approaches offer prospects for treatment of Hodgkin’s lymphoma.

In this article we present results of radiotherapy and combined modality treatment of 1882previously untreated patients with Hodgkin s lymphoma (HL) stages I, II, Ie, IIe at MRRC RAMS (Obninsk) between 1968 and 2006. Frequency and types of second malignancies, female fertility are presented too. 25-years overall survival rate was 59,1%, disease-specific survival — 73,2%, freedom from treatment failure — 46,8% after the radical program of radiotherapy. These rates in female patients with HL stages IA, IIA and histological subtype nodular sclerosis resulted 86,5%, 93,7%, 82,2% respectively. 20-years overall survival rate was 80,7%, disease-specific survival — 85,1%, freedom from treatment failure — 81,1% after combined modality treatment. In favorable prognosis group 36-month overall survival was 100% with no recurrences after 6 cycles of chemotherapy COPP followed by radiotherapy in total doses of20—24Gy. In intermediate prognosis group overall and disease-specific survival were 97,1%, freedom from treatment failure survival — 84,1% after 6—8 cycles ABVD followed by involved field radiotherapy in total doses 36Gy.

Methods: Were examined 145 patients with Hodgkin’s lymphoma (HL) II-IIIAB who received AHF within 1985-1997. A comparison was carried out with the comparable group of 110 patients given CF. The AHF schedule was carried out by admission of the single dose 1,35 Gy twice a day with interval 3,54 hs to basic registration points (bifurcation of trachea and paraaortal lymphatic nodes). The total doses in clinically involved nodes were approximately 40 Gy; zones of subclinical involvement — 36 Gy.

Results: Objective response was obtained 87,4% in the AHF group and 90,0% in the CF group. Median follow-up was 144 months: AHF - 144 months, CF — 150 months. Quantity of recurrences was significantly higher in patients with CF than in those with AHF — 28,3% and 16,5% (p=0,02), respectively. 10-years overall survival was 82,8% in AHF group and 72,1% in the CF group. 10-year recurrence-free survival was 81,5% in the AHF group and 69,8% in the CF group (p=0,04). Analysis of clinical date showed essential reduction of radiation pneumonitis rate at AHF in comparison with CF: 13,1% vs. 25,4% (p=0,01), postradiation pericarditis: 2,1% vs. 7,3% (p=0,04), leucopenia grade IV: 4,1% vs. 12,7%.

Conclusions: Clinical analysis revealed the benefits of single dose decrease from 2 Gy to 1,35 Gy at the twice a day irradiation scheme. The AHF is an effective schedule of RT and promotes to the recurrence frequency reduction, increases recurrence-free survival, decreases of the cardiopulmonary complication risk and leucopenia rate.

We report the brief analysis of basic treatment directions for last 80 years and our own 30-years results of therapy (total: 566patients) under consistent treatment protocols. We determined the benefit ofpatients division on prognostic groups according to tumor burden for a treatment choice. It was demonstrated the advantage of modern chemo-radiotherapy programs of last generation over radical radiotherapy and chemotherapy, and also the combined modality programs of last generation over previous treatment options. Our data showed the ability to achieve the equally high results in all prognostic groups at carrying out of the modern combined modality programs of last generation without treatment regimen deviations: the 5-years overall survival was 98 %, 95 % and 90 % in favorable, intermediate and poor prognosis groups respectively. These outcomes were similar to results of the large research centers. Adequate planning of studies at introduction in practice new treatment programs is discussed.

Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a median age of 65 years (range, 38—79 years). The median number of previous treatments was 3 (range, 1-9). For patients who received bortezomib plus dexamethasone the overall response rate was 73%. 38% patients achieved CR. CR in patients receiving bortezomib plus dexamethasone earlier vs later (≤ 3 и ≥ 4 line chemotherapy) were: 48% vs 27,5%. Bortezomib is active in patients with relapsed MM, including elderly patients. Side effects were predictable and manageable; principal toxicities were hematological, gastrointestinal, and peripheral neuropathy. The most common adverse events reported were asthenia (52%), neuropathy (53%), thrombocytopenia (32%), anemia (30%). Neuropathy greater than grade 2 was more frequent in patients who received 3 or more prior therapy regimens.

The aim of the investigation was to estimate Vero-Fludarabine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients. We report the activity of three combinations of Vero-Fludarabine, one with cyclophosphamide (Vero-FluCy), the second with cyclophosphamide plus rubida (Vero-FLUCYr) and 3^rd with rituximab (VeroFCR). For patients with chronic lymphocytic leukemia who received Vero-FluCy the overall response rate was 66.6%. Of the 9 patients, who received Vero-FluCy, 33.3% achieved complete remission and 33.3% partial remission. For patients with follicular lymphoma grades 1 and 2 who received Vero-FLUCYr or VeroFCR the overall response rate was 100%. The treatment was well tolerated. Hematologic toxicity included neutropenia and thrombocytopenia. 24% patients who received Vero-FluCy were complicated by infections. Nonhematologic toxicity was mild.

We conclude that Vero-Fludarabine is an effective treatment in previously untreated or in pretreated patients with chronic lymphocytic leukemia and follicular lymphomas.

This article demonstrates case report and review of literature of successful use Campath-IH in T-cell prolymphocytic leukemia.

Despite chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia and more than hundred years has passed from the moment of the first description of its clinical picture, the problem on nervous system involvement remains unresolved because of this kind of lesion remains _ very rarely sign of disease. There are less then ten case reports according to literary data. We observed just a one patient with CLL and diagnosed meningeal involvement at the hematologic department of Regional clinical hospital for more than thirty-year period. Clinical and laboratory symptoms were successfully treated by intrathecal administration of cytostatic agents.